Clinical trial of combined radio- and fluorescence-guided sentinel lymph node biopsy in breast cancer

British Journal of Surgery

Volumn 100, Issue 8, 2013, Pages 1037-1044

  Schaafsma, B E ^a   Verbeek, F P R ^a   Rietbergen, D D D ^a,b   Van Der Hiel, B ^a   Van Der Vorst, J R ^a   Liefers, G J ^a   Frangioni, J V ^c   Van De Velde, C J H ^a   Van Leeuwen, F W B ^b   Vahrmeijer, A L ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Section of Interventional Molecular Imaging   (Netherlands)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLORING AGENT; DIAGNOSTIC AGENT; INDOCYANINE GREEN; MACROSALB TC 99M; RADIOPHARMACEUTICAL AGENT; TECHNETIUM TC 99M NANOCOLLOID;

ADULT; AGED; ARTICLE; BREAST; BREAST TUMOR; COMPARATIVE STUDY; EVALUATION; FEMALE; FLUORESCENCE; HUMAN; IMAGE GUIDED BIOPSY; LUNG CARCINOMA; LYMPH NODE METASTASIS; LYMPHOSCINTIGRAPHY; METHODOLOGY; MIDDLE AGED; NEAR INFRARED SPECTROSCOPY; PAGET NIPPLE DISEASE; PATHOLOGY; PEROPERATIVE CARE; SCINTISCANNING; SENTINEL LYMPH NODE BIOPSY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COLORING AGENTS; FEMALE; FLUORESCENCE; HUMANS; IMAGE-GUIDED BIOPSY; INDOCYANINE GREEN; INTRAOPERATIVE CARE; LYMPHATIC METASTASIS; LYMPHOSCINTIGRAPHY; MIDDLE AGED; RADIOPHARMACEUTICALS; SENTINEL LYMPH NODE BIOPSY; SPECTROSCOPY, NEAR-INFRARED; TECHNETIUM TC 99M AGGREGATED ALBUMIN;

EID: 84878843541     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.9159     Document Type: Article

References (33)

1. Cox CE, Pendas S, Cox JM, Joseph E, Shons AR, Yeatman T, et al. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg 1998; 227: 645-651.
2. Goyal A, Newcombe RG, Chhabra A, Mansel RE; ALMANAC Trialists Group. Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer-results of the ALMANAC validation phase. Breast Cancer Res Treat 2006; 99: 203-208.
3. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, et al.,; National Surgical Adjuvant Breast and Bowel Project. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 2007; 8: 881-888.
4. Zavagno G, De Salvo GL, Scalco G, Bozza F, Barutta L, Del Bianco P, et al.,; GIVOM Trialists. A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg 2008; 247: 207-213.
5. Straver ME, Meijnen P, van Tienhoven G, van de Velde CJ, Mansel RE, Bogaerts J, et al. Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial. Ann Surg Oncol 2010; 17: 1854-1861.
6. Schaafsma BE, Mieog JS, Hutteman M, van der Vorst JR, Kuppen PJ, Löwik CW, et al. The clinical use of indocyanine green as a near-infrared fluorescent contrast agent for image-guided oncologic surgery. J Surg Oncol 2011; 104: 323-332.
7. Hutteman M, Mieog JS, van der Vorst JR, Liefers GJ, Putter H, Löwik CW, et al. Randomized, double-blind comparison of indocyanine green with or without albumin premixing for near-infrared fluorescence imaging of sentinel lymph nodes in breast cancer patients. Breast Cancer Res Treat 2011; 127: 163-170.
8. van der Vorst JR, Schaafsma BE, Verbeek FP, Hutteman M, Mieog JS, Lowik CW, et al. Randomized comparison of near-infrared fluorescence imaging using indocyanine green and 99(m) technetium with or without patent blue for the sentinel lymph node procedure in breast cancer patients. Ann Surg Oncol 2012; 19: 4104-4111.
9. Abe H, Mori T, Umeda T, Tanaka M, Kawai Y, Shimizu T, et al. Indocyanine green fluorescence imaging system for sentinel lymph node biopsies in early breast cancer patients. Surg Today 2011; 41: 197-202.
10. Kitai T, Kawashima M,. Transcutaneous detection and direct approach to the sentinel node using axillary compression technique in ICG fluorescence-navigated sentinel node biopsy for breast cancer. Breast Cancer 2011; 19: 343-348.
11. Hirche C, Mohr Z, Kneif S, Murawa D, Hünerbein M,. High rate of solitary sentinel node metastases identification by fluorescence-guided lymphatic imaging in breast cancer. J Surg Oncol 2012; 105: 162-166.
12. Polom K, Murawa D, Nowaczyk P, Rho YS, Murawa P,. Breast cancer sentinel lymph node mapping using near infrared guided indocyanine green and indocyanine green-human serum albumin in comparison with gamma emitting radioactive colloid tracer. Eur J Surg Oncol 2012; 38: 137-142.
13. Hirano A, Kamimura M, Ogura K, Kim N, Hattori A, Setoguchi Y, et al. A comparison of indocyanine green fluorescence imaging plus blue dye and blue dye alone for sentinel node navigation surgery in breast cancer patients. Ann Surg Oncol 2012; 19: 4112-4116.
14. Wishart GC, Loh SW, Jones L, Benson JR,. A feasibility study (ICG-10) of indocyanine green (ICG) fluorescence mapping for sentinel lymph node detection in early breast cancer. Eur J Surg Oncol 2012; 38: 651-656.
15. Aoyama K, Kamio T, Ohchi T, Nishizawa M, Kameoka S,. Sentinel lymph node biopsy for breast cancer patients using fluorescence navigation with indocyanine green. World J Surg Oncol 2011; 9: 157.
16. Murawa D, Hirche C, Dresel S, Hünerbein M,. Sentinel lymph node biopsy in breast cancer guided by indocyanine green fluorescence. Br J Surg 2009; 96: 1289-1294.
17. Frangioni JV,. In vivo near-infrared fluorescence imaging. Curr Opin Chem Biol 2003; 7: 626-634.
18. Fujisawa Y, Nakamura Y, Kawachi Y, Otsuka F,. Indocyanine green fluorescence-navigated sentinel node biopsy showed higher sensitivity than the radioisotope or blue dye method, which may help to reduce false-negative cases in skin cancer. J Surg Oncol 2012; 106: 41-45.
19. Hojo T, Nagao T, Kikuyama M, Akashi S, Kinoshita T,. Evaluation of sentinel node biopsy by combined fluorescent and dye method and lymph flow for breast cancer. Breast 2010; 19: 210-213.
20. Nos C, Fréneaux P, Guilbert S, Falcou MC, Salmon RJ, Clough KB,. Sentinel lymph node detection for breast cancer: which patients are best suited for the patent blue dye only method of identification? Ann Surg Oncol 2001; 8: 438-443.
21. Buckle T, van Leeuwen AC, Chin PT, Janssen H, Muller SH, Jonkers J, et al. A self-assembled multimodal complex for combined pre- and intraoperative imaging of the sentinel lymph node. Nanotechnology 2010; 21: 355101.
22. van Leeuwen AC, Buckle T, Bendle G, Vermeeren L, Valdés OR, van de Poel HG, et al. Tracer-cocktail injections for combined pre- and intraoperative multimodal imaging of lymph nodes in a spontaneous mouse prostate tumor model. J Biomed Opt 2011; 16: 016004.
23. van der Poel HG, Buckle T, Brouwer OR, Valdés Olmos RA, van Leeuwen FW,. Intraoperative laparoscopic fluorescence guidance to the sentinel lymph node in prostate cancer patients: clinical proof of concept of an integrated functional imaging approach using a multimodal tracer. Eur Urol 2011; 60: 826-833.
24. Brouwer OR, Buckle T, Vermeeren L, Klop WM, Balm AJ, van der Poel HG, et al. Comparing the hybrid fluorescent-radioactive tracer indocyanine green-99mTc-nanocolloid with 99mTc-nanocolloid for sentinel node identification: a validation study using lymphoscintigraphy and SPECT/CT. J Nucl Med 2012; 53: 1034-1040.
25. Brouwer OR, Klop WM, Buckle T, Vermeeren L, van den Brekel MW, Balm AJ, et al. Feasibility of sentinel node biopsy in head and neck melanoma using a hybrid radioactive and fluorescent tracer. Ann Surg Oncol 2011; 19: 1988-1994.
26. Mieog JS, Troyan SL, Hutteman M, Donohoe KJ, van der Vorst JR, Stockdale A, et al. Toward optimization of imaging system and lymphatic tracer for near-infrared fluorescent sentinel lymph node mapping in breast cancer. Ann Surg Oncol 2011; 18: 2483-2491.
27. Nieweg OE, Tanis PJ, Kroon BB,. The definition of a sentinel node. Ann Surg Oncol 2001; 8: 538-541.
28. Chung A, Yu J, Stempel M, Patil S, Cody H, Montgomery L,. Is the '10% rule' equally valid for all subsets of sentinel-node-positive breast cancer patients? Ann Surg Oncol 2008; 15: 2728-2733.
29. Valdés Olmos RA, Tanis PJ, Hoefnagel CA, Nieweg OE, Muller SH, Rutgers EJ, et al. Improved sentinel node visualization in breast cancer by optimizing the colloid particle concentration and tracer dosage. Nucl Med Commun 2001; 22: 579-586.
30. Mariani G, Erba P, Villa G, Gipponi M, Manca G, Boni G, et al. Lymphoscintigraphic and intraoperative detection of the sentinel lymph node in breast cancer patients: the nuclear medicine perspective. J Surg Oncol 2004; 85: 112-122.
31. Kim C, Erpelding TN, Maslov K, Jankovic L, Akers WJ, Song L, et al. Handheld array-based photoacoustic probe for guiding needle biopsy of sentinel lymph nodes. J Biomed Opt 2010; 15: 046010.
32. Gioux S, Mazhar A, Cuccia DJ, Durkin AJ, Tromberg BJ, Frangioni JV,. Three-dimensional surface profile intensity correction for spatially modulated imaging. J Biomed Opt 2009; 14: 034045.
33. van den Berg NS, van Leeuwen FW, van der Poel HG,. Fluorescence guidance in urologic surgery. Curr Opin Urol 2012; 22: 109-120.